Comparing Bispecifics, ADCs, and CAR T-Cell Therapy for the Treatment of MM

Video

Dr Voorhees shares his perspective on bispecifics, ADCs, and CAR T-cell therapy in the treatment landscapes of R/R multiple myeloma.

Case: A 63-Year-Old Man with R/R Multiple Myeloma

Clinical Presentation:

Patient AG is a 63 y/o man.

  • PMH: Diabetes, Hypertension
  • SMH: Does not smoke or drink alcohol
  • In October 2018, AG was admitted from clinic with hypercalcemia (Ca 13.7) and anemia (Hb 10.6) after a right pathologic hip fracture.

Clinical Workup and Diagnosis:

  • Calcium: 11.7 mg/dL
  • M-protein, 2.1 g/dL
  • Hemoglobin: 11.2 g/dL
  • Elevated LDH
  • Albumin, 2.7 g/dL
  • SCr, 1.3 mg/dL
  • Bone marrow biopsy confirms 25% clonal plasma cells, FISH del(17p)
  • PET-CT confirms osteolytic bone lesions in both hips; SF diagnosed with IgG kappa multiple myeloma

Disease Relapse and Treatments:

  • AG was initiated on VRd (bortezomib, lenalidomide, and low-dose dexamethasone) in frontline setting
  • He subsequently relapsed and progressed on 3 lines of therapy including belantamab mafodotin
  • He was then enrolled in a clinical trial and started on treatment with the bispecific antibody, talquetamab following four prior lines of therapy
  • Talquetamab was started at a dose of 0.4 mg/kg every week SC

Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma

GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma

April 23rd 2024
Article

At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

The Myeloma Trial Result I Did Not See Coming

The Myeloma Trial Result I Did Not See Coming

April 17th 2024
Article

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Read More

FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

April 12th 2024
Article

The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.

Read More

Targeting Multiple Myeloma With the Latest Therapies

Targeting Multiple Myeloma With the Latest Therapies

April 9th 2024
Article

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Read More

FDA Approves Cilta-Cel for Earlier Lines of R/R Multiple Myeloma

FDA Approves Cilta-Cel for Earlier Lines of R/R Multiple Myeloma

April 6th 2024
Article

The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.

Read More